MASI Masimo Corporation

Apple Inc. AAPL has reintroduced the blood-oxygen monitoring feature to its Apple Watch lineup after U.S. Customs and Border Protection approved imports of the devices - a decision that medical technology firm Masimo Corp. MASI is now challenging in court.

MASI gains FDA clearance to expand O3 monitoring with delta hemoglobin parameters across all patient groups.

NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.

U.S. update restores Blood Oxygen to Apple Watch Series 9, Series 10, and Ultra 2. Masimo shares fall 3.4% as Apple reintroduces the disputed feature. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.